Skip to main
OKUR
OKUR logo

OKUR Stock Forecast & Price Target

OKUR Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OnKure Therapeutics Inc demonstrated a narrower-than-expected net loss of $1.14 per share for 2Q25, which reflects improved financial performance relative to prior estimates. The company's clinical candidate, OKI-219, exhibited promising tolerability, with no reports of hyperglycemia and only Grade 1 treatment-related adverse events, indicating a favorable safety profile. These factors contribute to a positive outlook for OnKure, suggesting potential advancements in their clinical pipeline and overall financial resilience.

Bears say

OnKure Therapeutics is projected to incur a significant net loss of $4.56 per share for the full year of 2025, indicating financial deterioration compared to previous estimates. Key risks contributing to this negative outlook include potential negative clinical results associated with its lead asset, OKI-219, as well as delays in advancing pipeline candidates and obtaining regulatory approvals. Additionally, the company faces competitive pressures from other selective PI3Kα inhibitors and the risk of long-term dilution impacting shareholder value.

OKUR has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OnKure Therapeutics Inc (OKUR) Forecast

Analysts have given OKUR a Buy based on their latest research and market trends.

According to 4 analysts, OKUR has a Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OnKure Therapeutics Inc (OKUR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.